GSK quits Stevenage for Cambridge in £400m R&D shift

GSK will close its long-running Stevenage research hub and relocate about 1,000 staff to a new R&D campus in Cambridge, backed by a £400 million investment. The phased move aims to finish by 2029, with some employees shifting to Ware in Hertfordshire as the drugmaker seeks faster science and cost savings.

Key Takeaways

• GSK plans to shut its Stevenage R&D hub and move roughly 1,000 staff to the Cambridge Biomedical Campus by 2029.
• The company is spending £400 million over three years on the Cambridge flagship site and upgrades at Ware.
• About 1,800 people currently work at Stevenage; GSK hopes most will relocate to Cambridge or Ware.
• Annual cost cuts of £1.9 billion over three years will help fund R&D and cushion the dolutegravir patent expiry.
• The new labs will focus on oncology, respiratory, hepatology, vaccines and HIV research.

For readers following corporate cash flows and long-term portfolio stories in our Wealth Hacks & Passive Income coverage, the GSK shift is a reminder that big pharma capital is being redirected toward collaboration hubs and late-stage science—not just headcount cuts.

What is GSK announcing about Stevenage and Cambridge?

According to the BBC, pharmaceutical giant GSK will close its Stevenage site after a 50-year presence and move approximately 1,000 staff into three new R&D buildings under construction on the Cambridge Biomedical Campus.

PA reporting carried by Eastern Daily Press adds that around 1,800 staff work at the Stevenage R&D hub today. The new Cambridge centre is described as a 300,000 sq ft flagship site that will house more than 1,000 scientists, with a phased staff move due by 2029.

GSK says the Cambridge location sits “in the heart of the UK life sciences Golden Triangle” and will “accelerate our R&D and help us deliver new, competitive products.” Some Stevenage-based employees will instead move to Ware in Hertfordshire, where existing R&D laboratories are set to be upgraded.

The company is hoping all Stevenage workers will relocate to either Cambridge or Ware, and it has said it hopes most staff will move with the business—helped by the newly opened Cambridge South Station and its direct services to Stevenage.

Why does the Cambridge Biomedical Campus matter for GSK?

GSK frames the campus as one of the world’s leading life-sciences ecosystems. The BBC reports more than 22,000 people work in life sciences there, including partners and collaborations already linked to GSK.

Named collaborations include the Cambridge Centre for Data-Driven Discovery, the Cambridge-GSK Translational Immunology Collaboration, the Cambridge-GSK Metabolic Science Collaboration, Cambridge Immune Ageing, the GSK-Teichmann Lab, and the company’s clinical unit at Addenbrooke’s Hospital.

The campus also houses rival AstraZeneca, Addenbrooke’s and Royal Papworth hospitals, with a new Cambridge Cancer Hospital under construction. GSK says the new site will feature state-of-the-art labs and infrastructure for oncology, respiratory, hepatology, vaccines and HIV.

Chief scientific officer Tony Wood said Cambridge has built one of the world’s best life-sciences ecosystems, with leading universities, hospitals and biotech companies. “The campus provides exceptional opportunities for collaboration,” he added, calling the move “a catalyst for faster, bolder medicines discovery.”

The Cambridge site will sit within GSK’s wider UK network of academic and scientific partners, including the University of Oxford, King’s College London, Imperial College, the University of Manchester, Wellcome and the Crick Institute.

How is GSK paying for the £400m move—and what about jobs?

GSK is spending £400 million over the next three years on the Cambridge relocation and related changes. Eastern Daily Press reporting on the company’s half-year update says annual costs are set to be cut by £1.9 billion over three years to fund investment, ramp up R&D and help offset the impact when key HIV treatment dolutegravir comes off patent.

Chief executive Luke Miels said the three-year cost-savings programme will “simplify the organisation and to reallocate capital and resources.” Savings will “primarily be reinvested, with some used to improve margins and profitability in the dolutegravir patent expiry period.”

On the Cambridge investment itself, Miels said it will accelerate R&D and deliver new, competitive products, adding that it “integrates GSK further into one of the world’s leading centres of knowledge and demonstrates the attractiveness of the UK’s life sciences ecosystem.”

It is understood some roles will be affected, including in support services, but GSK has not confirmed numbers. The firm has already been cutting jobs at Stevenage as part of a global R&D overhaul. In February, it confirmed around 350 R&D jobs were going across the US and UK, when more than 2,500 workers were based at Stevenage.

Interim figures cited in the same reporting showed first-half underlying core operating profit rose 8% on a constant-currency basis to £5.45 billion, with turnover up 5% to £16.04 billion. On a statutory basis, half-year total earnings fell 31% to £2.77 billion.

What should investors and income-focused readers watch next?

The announcement pairs a visible property and talent shift with a multi-year cost programme. For shareholders and income-oriented readers tracking dividend durability, the key disclosed levers are the £1.9 billion annual cost reduction target, reinvestment into late-stage R&D, and preparation for the dolutegravir patent cliff—not a newly invented income product.

Operationally, the milestones to watch are whether most of the roughly 1,800 Stevenage staff transfer to Cambridge or Ware, whether the three Cambridge buildings open on the stated timeline, and whether Ware upgrades absorb the overflow without further unconfirmed cuts.

Five years ago, GSK had talked up expanding Stevenage as a top medical research destination by the end of the decade. The BBC notes that Cambridge’s pull now appears stronger. That reversal matters for anyone reading corporate strategy as a capital-allocation story: the firm is choosing proximity to collaborators over deepening a long-held Hertfordshire footprint.

None of the sourced reporting guarantees share-price outcomes or passive-income yields. What it does confirm is a £400 million bet on Cambridge science density, a 2029 Stevenage wind-down, and a parallel drive to free cash through organisation-wide savings while rebuilding the medicine pipeline.

In short, GSK is trading a historic Stevenage research base for a denser Cambridge network—and funding that pivot with both fresh capital spending and aggressive cost discipline disclosed alongside its latest results.